<?xml version="1.0" encoding="UTF-8"?>
<p id="p0065">As of 1
 <sup>st</sup> June 2020, there are currently 124 candidate vaccines that are under development for prevention of COVID-19 listed by the WHO Health Organization (WHO) landscape summary 
 <xref rid="b0285" ref-type="bibr">[57]</xref> of which 10 candidate vaccines specifically designed for prevention of COVID-19 (
 <xref rid="t0005" ref-type="table">Table 1</xref> ) have entered phase 1, combined phase 1/2 or phase 2 human clinical trials in adults. Most of these trials are enrolling healthy adults (from age 18 years) only, with the upper age limit of inclusion ranging from 50 to 60 years. Two trials are enrolling young participants, one from aged ≥3 years and the other ≥6 years with no upper age limit in both. One combined phase I/II trial includes older adults (up to age 85 years), while another early phase I trial has been extended in May 2020 to include also older adults (to age 99 years) 
 <xref rid="b0290" ref-type="bibr">[58]</xref>, 
 <xref rid="b0295" ref-type="bibr">[59]</xref>.
</p>
